ApoB and Cardiovascular Risk

The Data

What ApoB counts. ApoB is the structural protein embedded in each atherogenic lipoprotein particle capable of depositing cholesterol in the arterial wall. Because there is one ApoB molecule per particle, blood ApoB concentration serves as a direct estimate of circulating atherogenic particle number [4]. LDL-C, by contrast, measures the mass of cholesterol carried inside LDL particles—a value that varies substantially per particle. When cholesterol-per-particle is low, LDL-C can appear unremarkable while particle number is elevated.

Genetics points to particle number as the causal exposure. Two independent Mendelian randomization approaches converge on the same conclusion. Richardson et al. (2020) used multivariable MR with genetic instruments for LDL-C, triglycerides, and ApoB; when modeled together, ApoB retained a robust association with coronary heart disease (OR 1.92 per 1 SD higher ApoB), while LDL-C attenuated and reversed [1]. Zuber et al. (2021) applied MR-BMA across 30 lipoprotein measures and found the top-ranked model contained ApoB only, selected consistently across sensitivity analyses [2]. The operator translation: when genetics serves as a long-run controlled experiment, ApoB behaves like the exposure signal; LDL-C behaves like a correlated readout that can mislead.

Large-cohort discordance shows real event-rate separation. Sniderman et al. (2024) tested the practical objection ("LDL-C and ApoB are highly correlated, so decisions rarely change") in 293,876 UK Biobank adults (median follow-up 11 years; 19,982 ASCVD events) [3]. ApoB and LDL-C were highly correlated (r = 0.96), yet ApoB ranges at fixed LDL-C were wide, and those differences mapped to outcomes. At LDL-C 130 ± 10 mg/dL, 10-year ASCVD event rates were 7.3% vs 4.0% for ApoB high vs low (≥1 SD above vs ≤1 SD below the mean). In adjusted models, residual ApoB remained associated with incident ASCVD after accounting for LDL-C and HDL-C (HR 1.06 per 1 SD), while residual LDL-C did not remain significant once ApoB was included.

Guidelines acknowledge ApoB, but LDL-C remains the default. The 2019 ESC/EAS dyslipidaemia guideline notes that LDL-C, non-HDL-C, and ApoB are highly correlated, but that discordance exists in around 20% of patients, providing ApoB goals as secondary targets in higher-risk states [5]. The 2018 ACC/AHA cholesterol guideline treats ApoB as a risk-enhancing factor "if measured," flagging triglycerides ≥200 mg/dL as a relative indication for ApoB measurement, while noting extra cost and variable lab reliability [6]. The core reason LDL-C persists is not evidentiary weakness; it is institutional inertia and workflow. Sniderman et al. (2024) summarizes bluntly: even after guidelines concluded ApoB is more accurate, LDL-C was retained as the primary marker, and neither ApoB nor non-HDL-C has displaced LDL-C in routine care [3].

What This Means for Quality of Life

• "Normal LDL-C" is not proof of low atherogenic particle exposure; a non-trivial minority sit in the discordant band where LDL-C understates particle number [3][4]
• The highest-yield use case is the quietly common profile: LDL-C looks acceptable, triglycerides run higher, and ApoB measurement is absent—major guidelines single out this triglyceride context as a reason to pull ApoB [5][6]
• ApoB is less about "today's risk" and more about cumulative exposure; Mendelian randomization studies are effectively long-horizon experiments that consistently treat ApoB as the exposure variable surviving adjustment for correlated lipid traits [1][2]
• The "my cholesterol is fine" objection is often a language problem: LDL-C is a cholesterol-mass statement, not a particle-number statement; Sniderman et al. (2024) shows those are not interchangeable even at the same LDL-C value [3]
• A useful secondary framing (clearly labeled): Peter Attia's Outlive treats ApoB as the central lipid number for long-horizon cardiovascular risk conversations; the persuasive force comes from the cohort and genetic evidence above, not from the book itself

The Longitudinal Question

ApoB is a biomarker with an unusually asymmetric failure mode. If LDL-C and ApoB are concordant, the extra information can be modest. If they are discordant, the difference can be the entire story [3]. The problem is that discordance is rarely detected by "standard" testing cadence because the standard cadence does not include ApoB at all, and because single-point interpretation tends to treat LDL-C as if it were a complete description of atherogenic burden.

At Nexus Bio, we treat cardiovascular risk the way a serious operator treats balance-sheet risk: the relevant information is the distribution over time, not a single reading. ApoB's value is not that it replaces every lipid metric; it is that it closes a known blind spot and can be trended across years. Mendelian randomization results are, effectively, the longest trendline available, and they point in one direction: particle number is the exposure that matters.

The One Thing To Do This Week

Pull the most recent lipid results. If ApoB is not listed, it was not measured. On the next blood draw, request ApoB alongside the standard lipid panel—particularly if triglycerides have been persistently elevated. Major guidelines already treat ApoB as an optional risk-enhancing marker and call out elevated triglycerides as a reason the ApoB number can add information beyond LDL-C [5][6].

Nexus Bio is biological performance analytics for men who think in horizons, not quarters. Subscribe to the newsletter — one entry like this a week, delivered Tuesdays.